ストックスクリーナーアプリを入手
40.11
0.72%
-0.29
前日終値:
$40.40
開ける：
$40.43
24時間の取引高:
1.78M
Relative Volume:
0.48
時価総額：
$4.36B
収益：
-
当期純損益:
$-95.90M
株価収益率:
-30.39
EPS:
-1.32
ネットキャッシュフロー:
$-79.09M
1週間 パフォーマンス:
-3.40%
1か月 パフォーマンス:
+55.53%
6か月 パフォーマンス:
+841.55%
1年 パフォーマンス:
+607.41%
1日の値動き範囲:
$38.78
$41.26
1週間の範囲:
$38.78
$41.83
52週間の値動き範囲:
$1.865
$48.26
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
名前
Terns Pharmaceuticals Inc
セクター
電話
650-525-5535 EXT.101
住所
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
TERN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
40.11 | 4.39B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-04 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-11-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-10-15 | 開始されました | Truist | Buy |
| 2025-09-17 | 開始されました | Barclays | Overweight |
| 2025-09-04 | 再開されました | H.C. Wainwright | Neutral |
| 2025-02-28 | 開始されました | William Blair | Mkt Perform |
| 2024-10-31 | 開始されました | Oppenheimer | Outperform |
| 2023-06-22 | 開始されました | Mizuho | Buy |
| 2023-06-07 | 開始されました | Jefferies | Buy |
| 2023-05-31 | 開始されました | ROTH MKM | Buy |
| 2023-05-08 | 開始されました | BMO Capital Markets | Outperform |
| 2023-02-14 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-02-07 | 開始されました | UBS | Buy |
| 2022-09-12 | 開始されました | H.C. Wainwright | Neutral |
| 2021-09-14 | 再開されました | Goldman | Buy |
| 2021-03-02 | 開始されました | Cowen | Outperform |
| 2021-03-02 | 開始されました | Goldman | Buy |
| 2021-03-02 | 開始されました | JP Morgan | Overweight |
すべてを表示
Terns Pharmaceuticals Inc (TERN) 最新ニュース
With 53% Institutional Ownership, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Is a Favorite Amongst the Big Guns - 富途牛牛
Terns Pharmaceuticals reports inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Tern Pharmaceuticals (TERN) Soars 630% on CML Treatment Best-in-Class Potential - Insider Monkey
Meet the 10 Market Stars Behind Millionaire-Making in 2025 - Insider Monkey
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Terns Pharmaceuticals stock slides today, testing the $40 level after December share sale - ts2.tech
Terns Pharmaceuticals stock soars after leukemia drug delivers big early responses in tough-to-treat patients - MSN
Terns Pharmaceuticals (TERN) price target increased by 75.91% to 54.63 - MSN
Terns Pharmaceuticals Earnings Notes - Trefis
Pharmaceutical Stocks To Follow TodayDecember 10th - MarketBeat
Terns Pharmaceuticals proposes $400M equity offering - MSN
Terns Pharmaceuticals (TERN) climbs 53% on stellar leukemia treatment trial - MSN
Truist Securities maintains Terns Pharmaceuticals (TERN) buy recommendation - MSN
Terns Pharmaceuticals (TERN) Is Down 7.7% After Strong TERN-701 Phase 1 DataHas The Bull Case Changed? - Sahm
Jim Cramer highlights massive gains for Terns Pharmaceuticals shareholders - MSN
Terns Pharmaceuticals (TERN) Price Target Increased by 75.91% to 54.63 - Nasdaq
Will Terns Pharmaceuticals Inc. stock gain from government policies2025 Bull vs Bear & Weekly High Potential Alerts - moha.gov.vn
How Terns Pharmaceuticals Inc. stock performs in weak economyEarnings Performance Report & High Conviction Trade Alerts - Улправда
Is Terns Pharmaceuticals Inc. stock attractive for long term wealth buildingJobs Report & Target Return Focused Stock Picks - Улправда
Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders - Finviz
Terns Pharmaceuticals unveils promising phase 1 trial data - MSN
Insider Trends: How Terns Pharmaceuticals Inc. stock performs in weak economyJuly 2025 Volume & Free Expert Approved Momentum Trade Ideas - Улправда
Is Terns Pharmaceuticals Inc. stock a contrarian buy2025 Price Momentum & Free High Accuracy Swing Entry Alerts - Улправда
Terns Pharmaceuticals (TERN) Stock Today (Dec. 18, 2025): Why Shares Are Sliding After the Rally, and What Analysts Forecast Next - ts2.tech
Jim Cramer Was Asked About These 11 Stocks - Insider Monkey
Operating cash flow per share of Terns Pharmaceuticals, Inc. – GETTEX:430 - TradingView — Track All Markets
Terns Pharmaceuticals (TERN) Stock Today: Latest News, Analyst Forecasts, and What to Watch (December 16, 2025) - ts2.tech
Terns Pharmaceuticals (TERN): Valuation Check After Strong CARDINAL Trial Data for CML Candidate TERN-701 - simplywall.st
Terns Pharmaceuticals, Inc. (TERN) Discusses Efficacy and Safety Data Update for TERN-701 in Chronic Myeloid LeukemiaSlideshow (NASDAQ:TERN) 2025-12-15 - Seeking Alpha
Terns CEO Amy Burroughs talks cancer drug trial win - CNBC
Biotech ETF SBIO Hovers Near Peak on Rally - ETF Database
Terns Pharmaceuticals raises $747.5 million in upsized offering - Traders Union
Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial - Finviz
10 Stocks Delivering Explosive 18-190% Gains - Insider Monkey
Terns Pharmaceuticals (TERN) Price Target Increased by 65.68% to 26.75 - MSN
Why Terns Pharmaceuticals (TERN) Is Up 73.6% After Upsized Equity Raise On Strong TERN-701 Data - Sahm
Terns Pharma (TERN) Stock Analysis Report | Financials & Insights - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Terns Pharmaceutical prices stock at $40 per share - MSN
Citizens Maintains Terns Pharmaceuticals (TERN) Market Outperform Recommendation - MSN
Terns Pharmaceuticals raises $747.5 million in public offering - Investing.com
Terns Pharmaceuticals raises $747.5 million in public offering By Investing.com - Investing.com Australia
Terns Pharmaceuticals price target raised to $58 from $28 at Oppenheimer - MSN
Terns Pharmaceuticals Inc (TERN) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):